CorMedix (NASDAQ:CRMD - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect CorMedix to post earnings of $0.20 per share and revenue of $29.88 million for the quarter.
CorMedix (NASDAQ:CRMD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.08. The business had revenue of $39.74 million during the quarter, compared to the consensus estimate of $29.88 million. CorMedix had a return on equity of 59.43% and a net margin of 42.11%. The business's quarterly revenue was up 4830.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.25) EPS. On average, analysts expect CorMedix to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
CorMedix Stock Down 4.4%
Shares of CorMedix stock traded down $0.48 during trading hours on Friday, reaching $10.33. 8,503,029 shares of the stock traded hands, compared to its average volume of 2,452,521. The company has a 50 day moving average price of $12.52 and a 200 day moving average price of $10.80. The firm has a market capitalization of $700.58 million, a price-to-earnings ratio of 13.77 and a beta of 1.71. CorMedix has a one year low of $3.61 and a one year high of $17.43.
Institutional Trading of CorMedix
An institutional investor recently raised its position in CorMedix stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) by 4.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,987 shares of the company's stock after purchasing an additional 1,631 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.05% of CorMedix worth $222,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.18% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
CRMD has been the subject of a number of recent research reports. HC Wainwright cut their price objective on CorMedix from $20.00 to $17.00 and set a "buy" rating for the company in a research note on Friday. Needham & Company LLC boosted their price objective on CorMedix from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, June 24th. Royal Bank Of Canada upgraded CorMedix from an "outperform" rating to a "moderate buy" rating and boosted their price objective for the company from $13.00 to $17.00 in a research note on Friday, June 20th. Wall Street Zen downgraded CorMedix from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, D Boral Capital downgraded CorMedix from a "strong-buy" rating to a "hold" rating in a research note on Monday, June 30th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.71.
Read Our Latest Research Report on CorMedix
CorMedix Company Profile
(
Get Free Report)
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Read More
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access